AIR Brings World-Leading Inhalation Product Portfolio to InterTabac, as Demand for Shisha Surges Among Business Owners
8.9.2025 08:00:00 CEST | Business Wire | Press Release
Advanced Inhalation Rituals (AIR), the world’s leading social inhalation business, will be showcasing its most comprehensive portfolio to date at this year’s InterTabac, the world’s leading trade fair for tobacco products and smoking accessories, taking place from 18 – 20 September 2025 in Dortmund, Germany.
From the heritage of Al Fakher, the world’s #1 shisha brand, to OOKA, AIR’s revolutionary charcoal-free shisha device, visitors to InterTabac will gain a first-hand look at how AIR is shaping the future of shisha. Visitors will be able to sample flavors, explore breakthrough technologies, and discover how our multi-category portfolio creates new opportunities for lounges, retailers, and distributors alike.
The shisha market is not only growing – it’s evolving rapidly. AIR’s research shows that nine in ten (90%) businesses expect to see demand for shisha increase over the next two years, with strong optimism across the major markets of the UAE, US, Spain and Germany.
Findings from AIR’s survey of 400 hospitality businesses across Spain, Germany, the US, and the UAE show that consumer expectations are shifting rapidly, with greater focus on health, sustainability, and premium experiences:
- 87% now view sustainability and cleanliness as critical when selecting shisha solutions
- 32% believe charcoal-free shisha improves air quality and customer comfort
- 29% say adopting charcoal-free shisha solutions strengthens their reputation with eco-conscious guests
- 27% believe it will help attract more health-conscious customers
In response, AIR has built a portfolio that directly reflects these shifting consumer demands. At InterTabac 2025, the company will unveil its most comprehensive range to date, including:
- Al Fakher – The World’s #1 Shisha Brand
- Signature Collection: Globally loved classics, proven performers in every market
- Mixes: Single-flavor blends designed for endless customization
- Crafted Mixes: Layered, expertly blended profiles by Al Fakher’s shisha masters
- An exciting collaboration with an international icon and celebrity, featuring bold blends made to stand out
- Al Fakher Nicotine Pouches
- Tobacco-free, discreet, and infused with signature shisha flavors. Available in 6mg, 10mg, and 15mg strengths. Intertabac visitors will enjoy a first look at this range
- Crown Switch by Al Fakher
- A rechargeable pod system with switchable disposable pods, powered by Quantum Vape Technology™ for flavor-packed sessions
- OOKA Pro
- Revolutionary charcoal-free shisha devices for venues, with up to eight sessions on a single charge and a wide range of flavors
Stuart Brazier, CEO of AIR, commented: “InterTabac is the perfect stage to show how far AIR has come in the last two years. Across our portfolio, we’re redefining what shisha is today. While our approach remains deeply rooted in the social traditions at the heart of shisha, our focus on innovation is ensuring that we also give consumers and businesses what they increasingly expect around health, comfort, ease of use and sustainability.
“As the global appetite for shisha continues to grow, we’re proud to be leading the way in redefining what the experience looks like for the next generation. We are committed to helping our partners create cleaner, smarter, and more sustainable solutions that unlock real growth.”
A leading force in the industry, AIR is transforming the future of shisha. With advanced research, design and development capabilities in Dubai and production facilities in the UAE and Poland, AIR is scaling across categories to serve the evolving needs of lounges, retailers, and distributors worldwide.
Visitors to AIR’s stand at InterTabac (G10 and G06, Hall 8) will be able to experience the full multi-category portfolio first-hand, sample Al Fakher and OOKA flavors, and access exclusive trade offers.
Note to editors:
InterTabac is the world’s leading trade fair for tobacco products and smoking accessories. 14,500 visitors attended in 2024 and the 2025 event takes place from September 18-20 in Dortmund. More information is here: https://www.intertabac.de/en/.
About the research
- 400 Business Owners (aged 18+) at hospitality businesses that sell shisha across Spain, Germany, US, and UAE between 19.02.2025 - 24.02.2025 by Censuswide.
Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council.
About AIR
AIR is the market leader in the $19 billion global shisha market, with an aim to provide superior physical, emotional, and mental benefits through inhalation.
Launched in 1999 and headquartered in Dubai, the business has a multinational presence in over 100 countries across the UAE, Europe, North America, India, and Africa. AIR holds 47% of the shisha category market share in the markets it is present in and is the leading business in a market set to grow to $22 billion in 2026. Its portfolio of companies includes Al Fakher, the world’s leading shisha brand; Hookah-Shisha.com, the world’s number one e-commerce platform for hookahs and shisha; OOKA, the world’s first charcoal-free shisha device, among others. AIR’s science program, conducted in partnership with independent accredited laboratories, enables the development of innovative products that combine centuries of tradition with cutting edge innovation to minimize harm and maximize enjoyment for millions around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250907187544/en/
Contacts
Media contact
Boldspace
airglobal@boldspace.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom